Pakbaz Zahra, Wun Ted
Division of Hematology Oncology, Davis School of Medicine, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA.
Division of Hematology Oncology, Davis School of Medicine, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA; UC Davis Clinical and Translational Sciences Center, VA Northern California Health Care System, Sacramento, CA, USA.
Hematol Oncol Clin North Am. 2014 Apr;28(2):355-74. doi: 10.1016/j.hoc.2013.11.011. Epub 2014 Jan 18.
Recent studies suggest that sickle cell disease (SCD) is a hypercoagulable state contributing to vaso-occlusive events in the microcirculation, resulting in acute and chronic sickle cell-related organ damage. In this article, we review the existing evidence for contribution of hemostatic system perturbation to SCD pathophysiology. We also review the data showing increased risk of thromboembolic events, particularly newer information on the incidence of venous thromboembolism. Finally, the potential role of platelet inhibitors and anticoagulants in SCD is briefly reviewed.
最近的研究表明，镰状细胞病（SCD）是一种高凝状态，会导致微循环中的血管闭塞事件，从而造成急慢性镰状细胞相关器官损伤。在本文中，我们回顾了现有证据，证明止血系统紊乱对SCD病理生理学的影响。我们还回顾了显示血栓栓塞事件风险增加的数据，特别是关于静脉血栓栓塞发生率的最新信息。最后，简要回顾了血小板抑制剂和抗凝剂在SCD中的潜在作用。
